Research press release


Nature Medicine

An engineered antibody for treating hemophilia



Takehisa Kitazawaたちは、新たな治療方法として、第VIII因子活性をもつ抗体を作成した。第VIII因子は、第IXa因子と第X因子という別のタンパク質を血液凝固カスケードに持ち込み、この2つを結びつける働きをする。新たにつくられた抗体は、第VIII因子を真似て第IXa因子、第X因子に結合し、これらを適切に配置する。血友病で、しかも第VIII因子に対する抗体をもつ患者由来の血液でも、この新しい抗体によって血液凝固活性が回復した。また血友病Aの前臨床モデルとなるカニクイザルで、この抗体により出血が減少した。


An antibody that can functionally replace the missing protein in a type of hemophilia reverses the inability to stop bleeding in a non-human primate model of the disease, as reported in a paper published online this week in Nature Medicine.

Patients with hemophilia A lack the coagulation protein factor VIII and are typically treated by injection of FVIII protein. However, there is a need for new treatments, as over time patients often develop antibodies to the injected FVIII that block its efficacy. Even when effective, FVIII must be given frequently by intravenous injection, which poses a problem, particularly for children.

In a new treatment strategy, Takehisa Kitazawa and colleagues generated an antibody with factor VIII activity. Factor VIII works by bringing two other proteins in the blood coagulation cascade, factor IXa and factor X, into contact with each other. The new antibody mimics factor VIII, binding to and positioning factor IXa and X. This antibody restored coagulation activity in blood from humans with hemophilia, even those with factor VIII antibodies, and reduced bleeding in a preclinical model of hemophilia A in cynomolgus monkeys.

Compared to factor VIII injection, this antibody has the potential advantages of being unaffected by factor VIII antibodies and being easier to use (the antibody could be injected under the skin and would not require frequent injections). Further optimization of the antibody may be needed before it is ready to be tested in clinical trials.

doi: 10.1038/nm.2942


メールマガジンリストの「Nature 関連誌今週のハイライト」にチェックをいれていただきますと、毎週各ジャーナルからの最新の「注目のハイライト」をまとめて皆様にお届けいたします。